Sun Pharma Q4 Preview: PAT may grow 6% YoY; domestic business to drive revenue
Sun Pharma
is likely to see high single-digit growth in its bottom line in the fourth quarter on the back of continued outperformance in the domestic business. According to an average estimate of five brokerages, revenue is expected to grow 9% year-on-year (YoY).
Meanwhile, net profit for the reporting quarter will lag the revenue as an average of five estimates showed 6% YoY growth.
Analysts are building in $500 million US sales in 4QFY25, primarily due to higher gRevlimid sales. Meanwhile, gross margins are seen declining 30 bps QoQ to 79.7% due to lower milestone income.
For the specialty business, there is 20% YoY growth expectation at $325 million for 4Q owing to steady execution.
Here's what brokerages expect from Sun Pharma's Q4
Kotak Equities
We expect Sun Pharma's 4QFY25 overall sales to grow 8% YoY. For the global specialty business, we bake in a 17% QoQ sales decline to $308 million in 4QFY25, as specialty sales in 3QFY25 had inventory buildout and seasonality benefit. We build in a 9% YoY growth in India and a 9% YoY growth in RoW/EMs for 4QFY25.
We expect Sun Pharma's 4QFY25 gross margins to decline 30 bps QoQ to 79.7% due to lower milestone income. We bake in R&D spends at 7.7% of sales in 4QFY25 (+150 bps QoQ). On the EBITDA front, we factor in a 12% YoY growth to Rs34.7 bn, with an EBITDA margin decline of 390 bps QoQ to 26.8% due to higher R&D spend.
Motilal Oswal
Expect DF sales to grow 13% YoY for the quarter. Clarity on the launch of Deuruxolitinib in the US market and watch out for the launch in other global markets. Factors to drive consistent growth in branded generics in emerging/ROW markets. Any further progress on products in Amplitude basket.
YES Securities
Revenue decline seen as Q3 had one-off milestone income in ROW markets coupled with sequential fall in domestic business. US to inch up 2% QoQ on likely better Taro numbers (based on historical pattern). Higher R&D vs Q3 to dampen margin QoQ.
Nuvama
We build Sun Pharma's revenue to grow by 9% YoY as domestic business continues its outperformance at 10%. We build US revenue at $503 million and global specialty business at $335 million, with dermatology product sales seeing improvement. R&D spend is expected to be at 6.4% of the sales. We estimate EBITDA/PAT to grow by 22%/4% YoY with EBITDA margins at 28.4% for Q4FY25.
(
Disclaimer
: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of Economic Times)
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
an hour ago
- Time of India
Paytm shares hit Rs 1,000-mark on business recovery, revenue growth
After taking a sustained hammering on the bourses in the wake of its regulatory challenges, Paytm parent One 97 Communications ' shares have bounced stock has rallied 117% in the past 12 months, compared to a 1.9% rise in the Sensex. It is trading close to its 52-week high of Rs 1,063 per share, seen in mid-December company's shares touched the Rs 1,000-mark for the first time in six months on Wednesday, during a five-day rally. The stock cooled off in Thursday's session amid selling counter opened at Rs 1,005.25 apiece on the BSE today, against the previous close of Rs 1,004.50 per share. The stock closed at Rs 999, down 0.55%, against a 0.45% decline in the benchmark Sensex. Paytm has been recovering after being hit by regulatory actions last year. The company got approval from the National Payments Corporation of India (NPCI) last October to restart onboarding Unified Payments Interface (UPI) customers after an eight-month ban. The licence came after the Reserve Bank of India advised the UPI operator to review Paytm's request to become a third-party application provider (TPAP) and diversify app providers to reduce concentration then, the digital payments platform has been working to add UPI customers through its partner banks: Yes Bank HDFC Bank and State Bank of India The company is also gradually improving its business metrics, led by healthy momentum in the merchant business, according to brokerage Motilal Oswal. Meanwhile, disbursement volumes and gross merchandise value (GMV) are also growing at a steady of customer onboarding, a stable number of monthly transacting users (MTUs), and continued recovery in the financial services business are likely to drive healthy growth in revenues for Paytm, analysts at Motilal Oswal parent saw its consolidated net loss slightly narrow to Rs 540 crore in the three months ended March 2025, from a Rs 550 crore loss in the same quarter last year. The company had stated that its bottom line, without exceptional losses, is at a breakeven point. For the March quarter, Paytm recorded exceptional losses of Rs 522 crore, including a one-time Esop cost of Rs 492 crore Paytm's Esop cost is expected to drop to Rs 75 crore in the June quarter, from Rs 169 crore in the March quarter. The company said it achieved an operational profit of Rs 81 crore, after excluding Esop costs, in the March revenue declined 16% year-on-year to Rs 1,912 crore in Q4FY25 from Rs 2,267 crore a year ago. The company is scheduled to post its financial results for the June quarter on July has expressed strong confidence in its merchant loan distribution business, where it assists with both distribution and company has now begun providing a Default Loss Guarantee (DLG) for select portfolios with specific lenders. This move, according to Paytm, will help expand its merchant base and enhance its financial services revenue in the long factoring in the cost of DLG, Paytm's contribution margin (excluding UPI incentives) has grown to 54%, on improved payment processing margins and rising high-margin financial services income. The company expects these margin trends to continue. Contribution margin refers to the revenue left with a payments platform after deducting variable costs for processing the transactions.
The Hindu
7 hours ago
- The Hindu
Markets trade lower after firm start, fresh foreign fund outflows dent sentiment
Equity benchmark indices Sensex and Nifty started the day on a firm note on Thursday (July 17, 2025) but later faced selling pressure, with investors remaining in a wait-and-watch mode, as hopes are pinned on a favourable outcome from the U.S.-India trade talks. Fresh foreign fund outflows also dented investors' sentiment as they preferred staying on the sidelines. The 30-share BSE Sensex climbed 119.05 points to 82,753.53 in opening trade. The 50-share NSE Nifty went up by 18.7 points to 25,230.75. However, later the BSE benchmark quoted 71.51 points lower at 82,554.47, and the Nifty traded 30.30 points down at 25,182.55. From the Sensex firms, Sun Pharma, Tata Motors, Kotak Mahindra Bank, Trent, NTPC and Bharat Electronics were among the gainers. However, Tech Mahindra declined over 1% after its June quarter earnings failed to cheer investors. IT services firm Tech Mahindra reported a nearly 34% year-on-year increase in consolidated net profit to ₹1,140.6 crore for the quarter ending June 30, 2025, on the back of growth in communications and financial services verticals. ICICI Bank, Eternal, State Bank of India and Asian Paints were also among the laggards. 'There are no triggers for the market to break out of the consolidation range in which it has been stuck for two months now. Even an India-U.S. interim trade deal has been discounted by the market, leaving no scope for a sharp rally decisively breaking the range. One positive and surprise factor that can trigger a rally is a tariff rate much below 20%, say 15%, which the market has not discounted. So, watch out for developments on the trade and tariff front,' V.K. Vijayakumar, chief investment strategist, Geojit Investments Limited, said. Results of the IT sector continue to disappoint and, therefore, this can remain a drag on the overall market, he added. In Asian markets, Japan's Nikkei 225 index, Shanghai's SSE Composite index and Hong Kong's Hang Seng traded in the positive territory while South Korea's Kospi quoted lower. The U.S. markets ended higher on Wednesday (July 16). Foreign Institutional Investors (FIIs) offloaded equities worth ₹1,858.15 crore on Wednesday (July 16), according to exchange data. 'Markets appear to be in a wait-and-watch mode, eyeing a major trigger to scale Nifty's all-time high of 26,277.35. Hopes are pinned on a favourable outcome from the U.S.-India tariff talks,' Prashanth Tapse, Senior VP (Research), Mehta Equities Ltd., said. Global oil benchmark Brent crude climbed 0.58% to $68.92 a barrel. On Wednesday (July 16), the Sensex edged up 63.57 points or 0.08% to settle at 82,634.48. The Nifty ended 16.25 points or 0.06% higher at 25,212.05.
New Indian Express
7 hours ago
- New Indian Express
Markets trade lower after firm start, fresh foreign fund outflows dent sentiment
MUMBAI: Equity benchmark indices Sensex and Nifty started the day on a firm note on Thursday but later faced selling pressure, with investors remaining in a wait-and-watch mode, as hopes are pinned on a favourable outcome from the US-India trade talks. Fresh foreign fund outflows also dented investors' sentiment as they preferred staying on the sidelines. The 30-share BSE Sensex climbed 119.05 points to 82,753.53 in opening trade. The 50-share NSE Nifty went up by 18.7 points to 25, later the BSE benchmark quoted 71.51 points lower at 82,554.47, and the Nifty traded 30.30 points down at 25,182.55. From the Sensex firms, Sun Pharma, Tata Motors, Kotak Mahindra Bank, Trent, NTPC and Bharat Electronics were among the gainers. However, Tech Mahindra declined over 1 per cent after its June quarter earnings failed to cheer investors. IT services firm Tech Mahindra reported a nearly 34 per cent year-on-year increase in consolidated net profit to Rs 1,140. 6 crore for the quarter ending June 30, 2025, on the back of growth in communications and financial services verticals. ICICI Bank, Eternal, State Bank of India and Asian Paints were also among the laggards. "There are no triggers for the market to break out of the consolidation range in which it has been stuck for two months now. Even an India-US interim trade deal has been discounted by the market, leaving no scope for a sharp rally decisively breaking the range. One positive and surprise factor that can trigger a rally is a tariff rate much below 20 per cent, say 15 per cent, which the market has not discounted. So, watch out for developments on the trade and tariff front," VK Vijayakumar, Chief Investment Strategist, Geojit Investments Limited, said. Results of the IT sector continue to disappoint and, therefore, this can remain a drag on the overall market, he added.
